Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05360615 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion pushed from Jul 1, 2026 to Jul 1, 2027
    • Eligibility criteria expanded, about 6 words
  2. Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Jul 1, 2024 to Jul 1, 2026
    • Site details revised
    v7
  3. Re-verified, no change to tracked fieldsv6
  4. Site details revisedv5
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jun 1, 2022 to Jul 1, 2022
    v4
  6. 2 versions Re-verified since May 18, 2022, no change to tracked fieldsv2-v3
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Effects of Empagliflozin compared with placebo in post severe acute kidney injury survivors, evaluated by MAKE365.
Trial Details
NCT Number NCT05360615
Lead Sponsor Chulalongkorn University
Conditions
(from sponsor)		 Empagliflozin in Post AKI Stage 2-3
Enrollment 147 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov